Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic. by Gagnon, Alain et al.
UCLA
UCLA Previously Published Works
Title
Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced 
Susceptibility to Death during the 2009 H1N1 Pandemic.
Permalink
https://escholarship.org/uc/item/0w06m1n8
Journal
mBio, 9(1)
ISSN
2150-7511
Authors
Gagnon, Alain
Acosta, Enrique
Hallman, Stacey
et al.
Publication Date
2018-01-16
DOI
10.1128/mBio.02091-17
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Pandemic Paradox: Early Life H2N2 Pandemic Influenza
Infection Enhanced Susceptibility to Death during the 2009
H1N1 Pandemic
Alain Gagnon,a,b Enrique Acosta,a Stacey Hallman,c Robert Bourbeau,a Lisa Y. Dillon,a Nadine Ouellette,a David J. D. Earn,d,e
D. Ann Herring,f Kris Inwood,g Joaquin Madrenas,h Matthew S. Millere,i
aDepartment of Demography, Université de Montréal, Montréal, Canada
bUniversité de Montréal Public Health Research Institute (IRSPUM), Montréal, Canada
cStatistics Canada, Ottawa, Canada
dDepartment of Mathematics and Statistics, McMaster University, Hamilton, Canada
eMichael G. DeGroote Institute for Infectious Diseases Research, McMaster University, Hamilton, Canada
fDepartment of Anthropology, McMaster University, Hamilton, Canada
gDepartment of Economics and Finance, Department of History, University of Guelph, Guelph, Canada
hLos Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Los Angeles, California, USA
iDepartment of Biochemistry and Biomedical Sciences, McMaster Immunology Research Centre, McMaster
University, Hamilton, Canada
ABSTRACT Recent outbreaks of H5, H7, and H9 influenza A viruses in humans have
served as a vivid reminder of the potentially devastating effects that a novel pan-
demic could exert on the modern world. Those who have survived infections with
influenza viruses in the past have been protected from subsequent antigenically
similar pandemics through adaptive immunity. For example, during the 2009 H1N1
“swine flu” pandemic, those exposed to H1N1 viruses that circulated between 1918
and the 1940s were at a decreased risk for mortality as a result of their previous im-
munity. It is also generally thought that past exposures to antigenically dissimilar
strains of influenza virus may also be beneficial due to cross-reactive cellular immu-
nity. However, cohorts born during prior heterosubtypic pandemics have previously
experienced elevated risk of death relative to surrounding cohorts of the same pop-
ulation. Indeed, individuals born during the 1890 H3Nx pandemic experienced the
highest levels of excess mortality during the 1918 “Spanish flu.” Applying Serfling
models to monthly mortality and influenza circulation data between October 1997
and July 2014 in the United States and Mexico, we show corresponding peaks in ex-
cess mortality during the 2009 H1N1 “swine flu” pandemic and during the resurgent
2013–2014 H1N1 outbreak for those born at the time of the 1957 H2N2 “Asian flu”
pandemic. We suggest that the phenomenon observed in 1918 is not unique and
points to exposure to pandemic influenza early in life as a risk factor for mortality
during subsequent heterosubtypic pandemics.
IMPORTANCE The relatively low mortality experienced by older individuals during
the 2009 H1N1 influenza virus pandemic has been well documented. However, re-
ported situations in which previous influenza virus exposures have enhanced sus-
ceptibility are rare and poorly understood. One such instance occurred in 1918—
when those born during the heterosubtypic 1890 H3Nx influenza virus pandemic
experienced the highest levels of excess mortality. Here, we demonstrate that this
phenomenon was not unique to the 1918 H1N1 pandemic but that it also occurred
during the contemporary 2009 H1N1 pandemic and 2013–2014 H1N1-dominated
season for those born during the heterosubtypic 1957 H2N2 “Asian flu” pandemic.
These data highlight the heretofore underappreciated phenomenon that, in certain
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instances, prior exposure to pandemic influenza virus strains can enhance suscepti-
bility during subsequent pandemics. These results have important implications for
pandemic risk assessment and should inform laboratory studies aimed at uncovering
the mechanism responsible for this effect.
KEYWORDS influenza virus, mortality, pandemics, susceptibility
Influenza A virus (IAV) continues to pose one of the most pressing threats to globalpublic health due to its propensity to cause pandemics (1, 2). Over the course of the
past 100 years alone, at least five such pandemics have occurred, including the 1918
H1N1 “Spanish flu,” the 1957 H2N2 “Asian flu,” the 1968 H3N2 “Hong Kong flu,” the
1977 “Russian flu,” and the 2009 H1N1 “swine flu” (3). Unlike seasonal influenza virus
epidemics, which occur as a result of point mutations in the viral hemagglutinin (HA)
protein that permits escape from preexisting antibodies (a phenomenon called anti-
genic drift), pandemics occur when a novel virus emerges from a reassortment between
two or more strains of influenza viruses. Usually, humans have little to no preexisting
immunity to these viruses, which originate from different species (“antigenic shift”). For
instance, the H1N1 virus responsible for the 2009 “swine flu” pandemic carried a mix of
swine, avian, and human influenza virus segments (4). As a result, pandemic viruses
often cause more severe illness and deaths than their seasonal counterparts (5),
especially in the younger portions of the population, who are unlikely to have been
exposed to ancestral strains.
Preexposure to antigenically related IAV strains in older cohorts has had a protective
effect on those cohorts during subsequent pandemics. During the 1918 H1N1 “Spanish
flu” pandemic, those born prior to 1890 are thought to have been partially protected
by a putative H1 virus that circulated prior to the H3Nx pandemic that occurred that
year (6–9). Similar protection has also been reported during the 1968 H3N2 “Hong Kong
flu” pandemic for those exposed to the 1890 “Russian flu” pandemic, which is thought
to have been caused by an H3Nx-like virus (7, 10), and again during the 2009 H1N1
“swine flu” pandemic for those exposed to 1918 H1N1 or immunized against the 1976
“Fort Dix, New Jersey” H1N1 virus (11–13). Exposure to heterosubtypic viruses (within
the same HA group) has also been shown in boost titers of broadly neutralizing
antibodies (bnAbs) that bind to the HA stalk domain (14–16), which at least partly
account for the levels of protection observed among the elderly in many instances.
Titers of bnAbs are known to be higher in the elderly as a result of repeated
exposures to the mosaic of strains that circulated in the past. Yet, as was demonstrated
recently for Mexico (17, 18), protection among the elderly usually vanishes quickly a few
years after a pandemic outbreak. Our current study shows a similar decrease in
protection among the elderly during the 2013–2014 H1N1 outbreak that followed the
2009 pandemic in the United States and Mexico. However, it also reveals an increased
susceptibility to death, both in 2009 and in 2013–2014 influenza season, for middle-
aged groups that cannot be interpreted as a mere “age shift” in the levels of protection
against the circulating virus but rather as an increased susceptibility to the new strain
for specific cohorts exposed early in life to a highly dissimilar pandemic strain.
While most IAV preexposures are thought to have either a net positive or neutral
impact on future infections, there are at least two earlier examples for which several
groups have suggested that prior exposure to IAV may have been deleterious. During
the 1918 Spanish flu pandemic, the peak mortality occurred for those around 28 years
of age (6–9). For individuals who were born in 1890, the first IAV to which these
individuals would have been exposed was the putative H3Nx 1890 “Russian flu”
pandemic virus (19). A peak in mortality was also observed during the 1968 H3N2
pandemic for those born at the time of the 1918 H1N1 Spanish flu (7). Several
hypotheses have been advanced to explain this phenomenon, including T cell-
mediated immunopathology (6, 20), antigenic imprinting (6, 8, 21), and developmental
abnormalities as a result of exposure to influenza virus while in utero (6, 8) or as a
neonate (6, 8, 22). However, most of these hypotheses remain untested.
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To determine whether other similar age-related effects may have occurred, we
calculated influenza mortality by year of birth in the United States and Mexico during
the 2009 H1N1 pandemic and during the subsequent H1N1 outbreak of 2013 to 2014.
Accordingly, we observed peaks in death counts, rates, and ratios from influenza for
those who were 52 years of age during the 2009 H1N1 IAV pandemic in both countries.
This corresponds to a birth year of 1957, which was the year of the H2N2 “Asian flu”
pandemic. Our data provide a new example of a scenario wherein those born during
an influenza pandemic experienced elevated mortality during a subsequent, hetero-
subtypic influenza pandemic.
RESULTS
To assess the specific age-related mortality caused by the 2009 H1N1 “swine flu”
pandemic, we first determined pneumonia and influenza (P&I) average mortality counts
per month by single-year age during the outbreak from September 2009 to January
2010 and for all influenza seasons (November to April) from the 1997–1998 influenza
season to the 2007–2008 influenza season in the United States and Mexico (Fig. 1). The
standard deviations used to build the confidence intervals around the seasonal aver-
ages were based on the rate of P&I deaths of the 11 seasons. The sensitivity analyses
in the supplemental material present confidence intervals for seasonal values as well as
for the H1N1 outbreaks using P-splines, thus providing a means to assess the precision
of these results (see Fig. S1 in the supplemental material). This section of the supple-
mental material also presents SiZer plots, which help provide statistical support in the
identification of regions of increase or decrease, as well as local maxima in the data
(Fig. S3).
As has been reported earlier (23), we observed lower mortality from P&I for the
elderly during the 2009–2010 pandemic compared to previous influenza seasons in the
United States. However, we also observed a surprising increase in mortality counts for
the individuals who were approximately 45 to 60 years old (born between 1949 and
1964). Closer inspection shows that a peak in mortality counts for this cohort occurred
for those who were 52 years of age, that is, for those born in 1957, the year of the H2N2
Asian influenza pandemic (Fig. 1A). The elevation in mortality for those up to 60 years
old suggests that early life exposure to the H2N2 pandemic strain was sufficient to
elevate risk, even if it was not necessarily their first exposure to influenza virus. This
peak is apparent, though less obvious in Mexico (Fig. 1B), for which there are also
noticeable increases in the number of P&I deaths among younger individuals, especially
infants, but also among people born at the time of the 1968 pandemic.
FIG 1 Average number of deaths from pneumonia and influenza (P&I) during the 2009 H1N1 influenza pandemic and during seasonal outbreaks from 1997
to 2008 in the United States (A) and in Mexico (B). Age is shown in years on the x axes. 95% C.I., 95% confidence interval.
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Next, we analyzed excess mortality (count) estimates for each age using the Serfling
method (see Materials and Methods) for the 2009 pandemic, adding the resurgent
2013–2014 influenza season estimates (24) (Fig. 2). Due to the fluctuation of the curves
at certain ages, we smoothed the data. For simplicity and to ease visualization, we first
used locally weighted scatterplot smoothing (lowess) to plot the smoothed curves.
Alternative methods of smoothing are presented in the supplemental material, includ-
ing confidence intervals, which confirm the trends presented here (see Fig. S2 and S4).
In comparison with our prior observations based on simple P&I tabulations, the
overall monthly death counts were smaller, since these new estimates should exclude
pneumonia deaths which were not caused, in principle, by influenza. The peak in excess
mortality observed for those who were 52 years old in 2009 (born in 1957) was also, in
relative terms, more pronounced in Fig. 2 than in Fig. 1, while the estimated numbers
of deaths at older ages are much lower. These findings are consistent with the peak in
excess mortality that was recently reported to occur at 50 to 54 years of age in the
United States with a traditional Serfling model (25); we argue in the discussion that the
peak at the exact age of 52 years, the midpoint of the 50-to-54 5-year age group, results
from an early life exposure to the 1957 H2N2 pandemic virus. The slight elevation in
mortality observed for those born in 1968 in Mexico noted in the P&I distribution
(Fig. 1B) also becomes much more apparent using the analysis shown in Fig. 2B.
Although it has received considerably less attention, the 2013–2014 H1N1 influenza
season was nevertheless at least as deadly as the 2009 pandemic, if not more so.
Despite the fact that the estimated number of deaths depends on the period chosen
to define the epidemic (Fig. S6), the number of deaths among the elderly and among
those aged 50 to 65 years old appeared higher in the 2013–2014 influenza season than
in 2009. More importantly, relative to the 2009 pandemic, the peak of mortality among
these middle-aged people is shifted to the right by about 4 to 5 years; this is particularly
striking in the results for Mexico, for which the shift to the right is apparent for people
born in 1968 as well as for people born in 1957 (see ellipses in Fig. 2B).
The surge in mortality in these cohorts was also marked by an ellipse in Fig. 3, which
depicts monthly rates of mortality from influenza, calculated by dividing the death
counts from Fig. 2 by the population at risk in each 1-year age category (see Materials
and Methods). Another local peak of influenza mortality for 24- to 26-year-old individ-
uals was also apparent in Fig. 3. This corresponds to an important antigenic change
resulting from the acquisition of a new glycosylation site by H1N1 viruses that circu-
lated after 1985 (26, 27).
FIG 2 Average number of influenza deaths per month estimated from Serfling models in the United States (A) and in Mexico (B). (A) For the U.S. data, the
months when mortality was higher than the “epidemic thresholds” established by the CDC were used to define epidemic periods (see Materials and Methods),
i.e., from October to January 2010 for the 2009 pandemic and from December 2013 to March 2014 for the 2013–2014 H1N1 outbreak. (B) For the Mexican data,
the months chosen to define epidemic periods were those with noticeable increases in the number of severe acute respiratory infections (SARI) cases in
reference 18.
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Figure 4 illustrates death rate ratios comparing the 2009 and 2013–2014 H1N1
outbreaks to the average seasonal flu from 1997 to 2008. To facilitate interpretation, we
depicted birth cohorts on the x axis, rather than ages. The similarities between the
Mexican and U.S. trends in Fig. 4 are remarkable. As is immediately obvious from Fig.
4, the ratios were quite low for those born at the time of the 1918 pandemic and high
at young ages (i.e., for the recent birth cohorts), especially during the 2009 pandemic,
a well-known trend (23, 28). Perhaps less well-known was the sudden drop in risk (both
in the United States and Mexico) during the 2013–2014 influenza season for cohorts
born after 1985. These individuals mounted a protective H1 antibody response focused
primarily on an epitope involving residue K133 (26). In contrast, the H1 antibody
response of individuals born prior to 1985 was focused on an epitope involving residue
K166 of the pandemic H1N1 (pH1N1) virus. When this residue mutated to K166Q in
2013–2014 influenza season, they were once again susceptible to infection (27). A local
peak in death rates is again immediately apparent during the 2009 pandemic for those
born in 1957, at the time of the H2N2 pandemic. This peak was a deviation from the
general decline in protection mediated by preexisting immunity (depicted by hatched
black lines, for clarity). Death rates in 2009 then dropped for those born between 1957
FIG 3 Monthly death rates from influenza as estimated from Serfling models. The death rates were obtained by dividing the estimated number of deaths by
the number of individuals in the population at risk during a 1-month period in the United States (A) and Mexico (B).
FIG 4 Death rate ratios of influenza mortality during the 2009 H1N1 influenza pandemic and the 2013–2014 seasonal H1N1 outbreaks. Ratios for H1N1 influenza
outbreaks in the United States (A) and Mexico (B) are relative to the average of values for influenza seasons from 1997 to 2008. The log (base 10) is used on
the y axes in order to preserve symmetry about a death rate ratio of 1 (i.e., the line at zero on a log scale). Gray vertical lines mark the 1918, 1957, and 1968
influenza epidemics. The dotted black lines depict the trend of increasing death rate ratios after 1918, as differential protection progressively declines.
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and 1968 as H2N2 became epidemic and caused fewer and less severe infections
among the population (29). Rates then continued to rise in cohorts born until the
mid-1980s when the aforementioned antibody focusing shifted to residue K133 (27).
Mortality rates from seasonal influenza are usually very low among adolescents and
young adults, which primarily accounts for the large risk ratios measured for these ages
during the 2009 pandemic. On the other hand, the attack rates for these ages were very
high during that pandemic (30), much more so than during usual epidemic seasons (see
Fig. 7), and to a point that school closures during the outbreak significantly slowed the
spread of the pandemic in Canada (31). In fact, the excess mortality of those who were
less than 30 years old was most likely the result of a high attack rate, and not of a high
case fatality rate. As seen in Fig. 5, the case fatality rate ratio (CFRR) of cohorts born after
about 1980 (i.e., less than 30 years old in 2009) was either lower or approximately equal
to 1 in the United States. This CFRR compares the case fatality rate of the 2009
pandemic to that of the previous 10-year average of seasonal outbreaks (see Materials
and Methods), meaning that children and young adults in 2009 had an equal or a lower
case fatality rate than those who were of the same ages during the previous seasons
of influenza. In Mexico, where the 2009 pandemic and the 2013–2014 influenza virus
seasons were more severe, the estimated case fatality ratios are larger. Yet, the
similarities between the results for two countries are again striking, with the exception
of an increased risk in Mexico for the 1968 cohort.
DISCUSSION
The results of this study are in agreement with previous studies which have reported
increased frequencies of cross-reacting antibodies against the H1N1 Cal09 virus in 2009
for individuals born between 1918 and the 1930s (32, 33). This protection, which can be
appreciated in Fig. 4, came as a result of exposure to the 1918 H1N1 “Spanish flu” virus,
and those viruses that circulated thereafter. Indeed, these viruses shared considerable
antigenic similarity with the 2009 H1N1 virus (4).
However, the peak in excess mortality for individuals born in 1957 during the 2009
“swine flu” pandemic cannot be fully explained by differential protection conferred by
FIG 5 Case fatality rate ratios (CFRRs) of influenza mortality during the 2009 H1N1 influenza pandemic.
Ratios of case fatality rates are relative to the average of values for influenza seasons from 1997 to 2008.
For both the 2009 pandemic and the reference flu seasons, age-specific case fatality rates were obtained
by dividing death rates by attack rates provided in Fig. 7 for each age. The log (base 10) is used on the
y axis in order to preserve symmetry about a case fatality rate ratio of 1 (i.e., the line at zero on a log
scale). Gray vertical lines mark the 1918, 1957, and 1968 influenza epidemics.
Gagnon et al. ®
January/February 2018 Volume 9 Issue 1 e02091-17 mbio.asm.org 6
preexisting immunity (see peaks above the dashed lines in Fig. 4). Although there is a
general trend of increasing mortality for those whose birth years left them less likely to
have been infected by a 1918-like H1N1 virus at a young age, it is clear that H1N1
disappeared from circulation upon emergence of the H2N2 pandemic strain in 1957
(19). Those born prior to 1957 would have experienced some protection conferred by
prior exposure to H1N1 viruses, but the peak in excess mortality declines sharply for
those born between 1958 and 1968 despite no further circulation of H1N1 viruses until
their reappearance in 1977. This is in close agreement with an interesting study that
showed a similar peak in influenza morbidity for those born around 1957, followed by
a steep drop for those born between 1958 and 1968 (34). This observation is also
consistent with historical data which reported both declining rates and severity of
H2N2 infection in the years after 1957 (29). This phenomenon has also been reported
for H1N1 viruses and has been ascribed, at least in part, to the accumulation of
glycosylation sites (35). Together, these factors would have attenuated the strength of
H2N2 “imprinting” at both the individual and population levels in the years following
1957.
The peaks in excess mortality observed during the 2009 H1N1 pandemic and
2013–2014 H1N1 epidemic year for those born in 1957 also mirror the mortality trend
observed during the 1918 Spanish flu for those born during the 1890 flu pandemic
(6–9). The data reported here thus demonstrate the susceptibility associated with birth
during the year of an influenza virus pandemic was not unique to 1890 and 1918 and
represent a previously unappreciated risk factor during subsequent pandemics. The
recurrence of this trend, which has all of the hallmarks of a cohort effect (9), highlights
the value of studying influenza mortality figures using single-year age data, instead of
the very large age groups that are in use in most, if not all, flu sentinel programs (e.g.,
0 to 4, 5 to 17, 18 to 64, and 65 years old). In some cases, the 0-to-64 age group is
simply compared with individuals who are more than 65 years old, a classification
which fails to reveal any eventual cohort effects.
Yet, in contrast to what was observed in Mexico, a mortality peak was not evident
in the United States in the 2009 pandemic or the 2013–2014 influenza season for those
born in 1968, the year of the H3N2 “Hong Kong flu” pandemic—a scenario that would
have been more analogous to that which occurred in 1918 for those born in 1890 (6).
This discrepancy between the U.S. and Mexican data could be explained by the fact that
the 1968 H3N2 and 2009 H1N1 pandemics were separated by a vast U.S. vaccination
campaign against swine flu in 1976. Exposure to the 1976 swine vaccine relatively early
in life may have resulted in more robust immunity against H1N1 viruses in general
compared to those who were born in 1957, who would have thus had much longer
influenza virus exposure history before receiving the vaccine.
Following the 2009–2010 influenza season where pH1N1 caused the vast majority
of infections, H3N2 viruses became the predominant source of infections between the
2010–2011 and 2012–2013 seasons. During the 2013–2014 influenza season though,
pH1N1 reemerged as the dominant cause of infections. Relative to the parental pH1N1
that emerged in 2009, the H1N1 strain that circulated in the 2013–2014 season was
found to carry a K166Q mutation in HA. Many middle-aged adults were found to have
antibodies specific for K at position 166, due to their exposure to seasonal H1N1 viruses
that circulated between 1977 and 1985 (27). Conversely, those born after 1985
mounted an antibody response focused on residue K133, and indeed experienced
reduced mortality in the 2013–2014 influenza season relative to the 2009 influenza
season (26). High attack rates in this cohort during the 2009 pandemic (as shown in
Fig. 7) may have also resulted in more robust population-level immunity. The replace-
ment of K with Q in the 2013–2014 influenza season is postulated to have reduced the
protective immunity of middle-aged adults (who were primed to K166), and may thus
explain the elevated death counts that we observed for these cohorts in the 2013–2014
influenza season relative to the 2009 season (36). These trends were remarkably
consistent in both the United States and Mexico (Fig. 3 and 4).
Strain-specific antibodies have historically been considered the primary correlate of
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protection against influenza viruses (37). Elicitation of these antibodies is therefore the
goal of current-generation influenza virus vaccines. Unfortunately, the strain-specific
nature of these vaccines does not offer protection against the emergence of pandemic
influenza virus strains, as was clearly demonstrated during the 2009 H1N1 “swine flu”
outbreak (38). This has highlighted the urgent need to develop more broadly protective
“universal” influenza virus vaccines—capable of providing protection against both
seasonal and pandemic influenza strains (2, 39). Recently, Gostic et al. (40) argued that
imprinting conferred by the first influenza virus to which an individual is exposed
provides lifelong cross-protective immunity to highly pathogenic avian influenza strains
from the same HA group. This was demonstrated using aggregate data from H5N1 and
H7N9 infections in the isolated regions where these epidemics have occurred. While
this phenomenon seems to hold true in many scenarios, our data suggest that this
principle is not universal.
The model set forth by Gostic et al. (40) would predict that during historical
pandemics, individuals first exposed to an influenza virus from within the same HA
group as the pandemic strain should be “protected” relative to individuals first exposed
to a strain belonging to a different HA group. Yet, as was observed in this study, people
born at the time of the 1957 H2N2 influenza pandemic (thus primed to a group 1 HA)
were at an increased risk of death during the 2009 H1N1 pandemic and the 2013–2014
resurgent H1N1 outbreak, which were also caused by a group 1 HA virus. Indeed, the
CFRR during the 2009 H1N1 pandemic of those born during the circulation of H2N2 (a
group 1 HA virus) noticeably exceeded that of those born between 1968 and 1977,
most of whom would have been likely primed by H3N2 (a group 2 virus). Of course, the
2009 H1N1 pandemic was somewhat unique, in that almost the entire population had
some degree of pre-exposure to H1N1 viruses that circulated previously—resulting in
varying degrees of cross-protection based on the antigenic similarity between the
H1N1 strain(s) to which cohorts were exposed and the pandemic strain itself.
When observed closely, data from Gostic et al. (40) show evidence that early life
exposure to the 2009 pH1N1 may have led to higher increases in the numbers of cases
and deaths during the following years from H5N1 than from H7N9, even though the
former is from group 1, while the latter is from group 2. We would suggest that the
increases in risk of severe infection from both H5N1 and H7N9 for the children born at
the time of the 2009 pandemic are the result of their commitment early in life to a
heterosubtypic pandemic influenza virus (i.e., H1N1) relative to both these two viruses.
It could also be suggested that the mortality peak observed for the cohorts born
between 1945 and 1965 is due to the higher susceptibility (by some unknown mech-
anism) of the baby boomers. Incidentally, the 1957 cohort is one of the largest cohorts
of the 20th century in the United States, and Lexis surfaces of all-cause mortality
indicate an increased mortality for cohorts centered around that year, beginning in the
period from 1980 to 1985 and persisting into the new millennium (41). In general, large
cohorts have fewer per capita resources, which could lead to increased levels of frailty
that pandemic outbreaks or severe influenza seasons would reveal with acuity, typical
of a harvesting effect. However, breaking down the analyses by specific causes of death
and using Serfling models applied to pneumonia and influenza, no large increase of
mortality from influenza itself is seen for these cohorts during all of those years (42),
some of which were appreciably more deadly than the 2009 and 2013–2014 outbreaks.
In other words, the excess influenza mortality centered on the 1957 generation is
observed for the 2009 pandemic and, perhaps less clearly, during the 2013–2014
outbreak, but not during previous, more severe influenza seasons. In addition, during
the 1968 H3N2 pandemic, children aged 11 years old and thus born during the 1957
H2N2 pandemic did not experience notable excess mortality (7). As indicated above,
death rate ratios from pneumonia and influenza mortality in 1968 peaked instead for
the cohorts born at the time of the 1918 pandemic, which were primed early in life to
a doubly heterosubtypic virus (H1N1) relative to the 1968 virus (H3N2). Further, despite
Mexico’s appreciably different past demographic trends (the largest cohorts in Mexico
were born later than in the United States, i.e., in the early 1960s), excess mortality also
Gagnon et al. ®
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peaks for the 1957 generation and yet again for the 1968 generation, without apparent
connection between cohort size and peak mortality during the 2009 H1N1 pandemic
and epidemic outbreak of the 2013–2014 influenza season.
The sheer size of the baby boom cohort could have had a role, not in directly making
the members of this cohort more susceptible to death from influenza, but in making
them much more likely to be infected with the H2N2 influenza virus very early in life
than would have been the case if the cohort were smaller. It is possible that infections
(priming with H2N2) at the time of birth or very early in life were more likely for the
most numerous cohorts of the baby boom (1956 to 1961) than for the previous or
following cohorts because of an increased rate of transmission. That increased fraction
of the cohorts primed to a doubly heterosubtypic virus (i.e., H2N2 relative to the swine
flu H1N1 virus) would have compounded its excess mortality in the 2009 and 2013–
2014 influenza seasons.
The observation that susceptibility during pandemics seems to be elevated most
profoundly for those primed early in life to doubly heterosubtypic viruses suggests that,
contrary to the cross-protective immune responses elicited by early life exposure to
antigenically similar viruses, priming by viruses with little-to-no antigenic overlap may
result in responses that promote pathogenicity. This could be due to excessive proin-
flammatory responses mediated by T cells specific for conserved internal antigens
and/or Fc-bearing cells that bind to cross-reactive, but nonneutralizing antibodies.
Alternatively, early life infection with a virulent doubly heterosubtypic virus may
compromise lung function (i.e., “scarring”) such that in the absence of cross-protective
immunity, exposure to an antigenically unrelated virulent pandemic virus later in life
causes exacerbated respiratory disease. These scenarios are not mutually exclusive, and
we hope that our data will inform investigations to experimentally define the mecha-
nism(s) at play. We recognize, however, that such experiments are challenging due to
both difficulties in recapitulating the complex exposure histories of adults and difficul-
ties associated with secondary infection of mice with influenza virus after a primary
exposure.
In conclusion, we believe that there is an important missing piece in the puzzle that
has been overlooked in most investigations concerning antigenic imprinting. Not only
can antigenic imprinting lead to differential protection based on year of birth and
exposure to antigenically related viruses in the past, but it can also lead to differential
susceptibility to severe outcome from IAV infection as a result of mechanisms that
appear to be distinct from those that explain differential protection. In all likelihood,
attack rates were not especially high for the 1957 cohort in 2009 (see Fig. 7), yet the
estimated CFRR was at its peak, suggesting the involvement of an aberrant immune
reaction following infection, leading to severe outcomes or death. Our study does not
allow for definitive conclusions to be drawn regarding the mechanisms which contrib-
ute to increased susceptibility. Importantly though, it provides a framework through
which this phenomenon can be tested in animal models by identifying specific viral
strains that can be used to recapitulate the exposure histories reported herein and
define the biological basis of our observations.
Taken together, the findings reported herein firmly establish that exposure to a
pandemic virus during the first years of life served as a susceptibility factor during later
heterosubtypic influenza virus pandemics or intense seasonal outbreaks, indicating that
it is not an isolated phenomenon. Developing experimental models to study the
biological basis of this phenomenon will be essential to informing policy guidelines
aimed at protecting high-risk groups during future pandemics.
MATERIALS AND METHODS
Data on monthly mortality by age and underlying cause from October 1997 to July 2014 were
obtained from the U.S. public-use data files of the National Center for Health Statistics (vital statistics data
available online at https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm) and from Mexico’s Insti-
tuto Nacional de Estadística y Geografía (INEGI) (http://www.beta.inegi.org.mx/proyectos/registros/
vitales/mortalidad/default.html?init2). We retrieved the monthly populations at risk by single year of
age from the “1-year exposure to risk” tables published for the United States in the Human Mortality
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Database (http://www.mortality.org/) and the 1-year population size published for Mexico by the Consejo
Nacional de Poblacion (CONAPO) (https://datos.gob.mx/busca/dataset/proyecciones-de-la-poblacion-de
-mexico). In order to describe and compare mortality from influenza during pandemic and seasonal
outbreaks, first we used raw pneumonia and influenza (P&I) counts, from which simple figures such
as death counts can be readily and advantageously calculated for single ages. We used the “epidemic
threshold” set by the Centers for Disease Control and Prevention (CDC) (Morbidity and Mortality Weekly
Report https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5929a2.htm and https://www.cdc.gov/
mmwr/preview/mmwrhtml/mm6322a2.htm) to define the 2009 and 2013–2014 outbreaks in the United
States, i.e., from October 2009 to January 2010, and from January to March 2014. No such analysis was
readily available for Mexico, and thus, we defined the periods from daily counts of severe acute
respiratory infections (SARI) deaths reported by Dávila-Torres et al. (18), i.e., from September 2009 to
January 2010 and from December 2013 to March 2014. These selected dates are, to a certain extent,
arbitrary and will lead to different numbers of deaths depending on the progression of the epidemic (the
elderly are usually hit last yet have larger numbers of casualties). Therefore, several alternative specifi-
cations of outbreak periods were tested with no fundamental alterations in the results (see Text S1 in the
supplemental material).
Since many of the deaths in the P&I category may be due to causes other than influenza (a
pneumonia death may occur as the result of another source of infection unrelated to influenza), we also
estimated “excess” mortality (strictly) from influenza with a Serfling model and a Serfling-inspired model
that accounts for virus circulation, called here the “surveillance-Serfling” model (43) and presented
below. We fit the surveillance-Serfling model to P&I deaths in the United States from October 1997 to July
2014, i.e., for the period during which both the indicators of influenza circulation and mortality data are
available on a monthly basis. The monthly indicators such as influenza-like illness (ILI) or the percentage
of respiratory specimens testing positive for influenza virus were taken from the World Health Organization
FluNet database (http://www.who.int/influenza/gisrs_laboratory/flunet/en/). However, even though circula-
tion data were available for Mexico, test applications of the surveillance-Serfling methods for this country
proved unreliable, most likely because of population size issues, which are especially pronounced with
single-year age data.
To favor specificity over sensitivity (25), we based our Serfling and surveillance-Serfling estimates on
pneumonia and influenza (P&I) as the underlying causes of death rather than on all-cause mortality or
other combinations, including respiratory and circulatory diseases, which are often involved in the
etiology of influenza-related deaths. As a matter of fact, the aberrant pathological immune response,
which we believe is implicated in the increased susceptibility to death of specific birth cohorts, is most
easily revealed when P&I causes of death are selected to estimate influenza mortality. Given the purpose
of this study, i.e., testing whether a birth during a specific (pandemic) year affects mortality from
influenza during a subsequent pandemic later in life, it is necessary to tabulate yearly statistics. For the
complete span of the 220 months under observation, i.e., from October 1997 to July 2014, we thus
summarized the deaths caused by P&I by single-year age. Since virus circulation data are not available
for single-year ages, we used instead virus circulation data by age group (0 to 4 years, 5 to 24 years, 25
to 64 years, and 65 years).
The Serfling model. Serfling regression is a method widely used to estimate influenza mortality. It
allows for the calculation of influenza mortality taking into account seasonal and secular mortality trends
(44). The basic formulation of the model is:
logdeathsa,t 
i0
5
it
i 6sin2t12  7cos2t12  logexposurea,t
where a is age in years (0, 1, 2, . . ., 100), t is the epidemic period (here from the 1997–1998 to the
2006–2007 seasons), the ’s are parameters to estimate, deathsa,t are the number of deaths, and
exposurea,t is the number of individuals at risk (population at risk). The Serfling model includes three
principal components: 
i0
5
it
i is here a fifth degree polynomial that controls for secular trends in
mortality, while the 6sin2t12   7cos2t12  term captures influenza seasonality, and logexposurea,t
accounts for changes in the distribution of the population by age (a) over time (t). This regression model
is estimated accounting exclusively for summer months (May to October), when influenza virus is not
supposed to circulate among the population of temperate regions. Influenza-related mortality is esti-
mated as the difference between the observed monthly death counts recorded from P&I and the Serfling
model-predicted death count.
In contrast to original applications of the Serfling method, which are based on linear regression
models or Poisson distributions (44), we use a negative-binomial distribution, which accounts for
overdispersion and allows for low-frequency-count data (45), which may indeed result from the single-
year age classification used here. One advantage of the Serfling model is that it requires only death
counts and the populations at risk by month and age. However, since it strongly relies on seasonal
variations, this model may capture deaths unrelated to influenza that are also seasonal in nature, and it
can produce incoherent estimates, such as negative numbers of deaths, as discussed by Nguyen and
Noymer (25). Such instances indeed occurred in the Mexican data at young ages, which we alleviated by
constraining the death count estimates to be equal or smaller than the observed P&I mortality, thereby
“forcing” negative estimates to zero.
The surveillance-Serfling model. Provided that indicators of influenza activity are available and
reliable, it is possible to use the surveillance-Serfling model, which may considerably improve the
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accuracy of the estimates (43, 44, 46, 47). In order to estimate mortality from influenza in the U.S. data,
we used the following specification:
logdeathsa,t 
i0
8
it
i 9sin2t12  10cos2t12  11sin3t12  12 cos3t12  13sin4t12 
 14cos4t12  15 sin6t12  16cos6t12  17sin8t12  18cos8t12 
 19sin10t12  20cos10t12  logexposurea,t 21PAN2009 22PAN2013
 23ILIg,t 24ILIg,t1
where a is age (0, 1, 2, . . ., 110), t is the monthly period (from October 1997 to July 2014), deathsa,t are
death counts (number of deaths), and exposurea,t are the populations (number of individuals) at risk of
age a at time t. As is the case for the traditional Serfling model, the sin and cos terms are harmonic
terms that control for influenza seasonality, 
i0
8
it
i accounts for secular trends in mortality, and log
exposurea,t tracks changes in the age structure of the population over time. Given age variations in
mortality over time, specific components were retained for each age, based on their statistical signifi-
cance (components with P values of 0.05 were rejected). The PAN terms are dummies that take the
value of 1 during either the 2009 or 2013–2014 H1N1 outbreaks and of zero otherwise. The ILIg,t term
introduces the monthly incidence of influenza-like illnesses (ILI) for each age group (0 to 4 years, 5 to 24
years, 25 to 64 years, and 65 years), including a 1-month lag term (t  1), since an influenza death
occurring during an index month may in fact result from an infection contracted the preceding month,
particularly among the elderly individuals (42). For sensitivity analyses, we dropped the lag term in order to
remove from the estimates the deaths arising from comorbidities and thus to sharpen our focus on deaths
from influenza alone; the results were increased relative mortality among the younger generations relative to
older generations (not shown here). As our earlier sex-specific analyses provided similar results for males and
females, we decided to regroup sexes in order to improve model fit.
We first fit the above model to deaths recorded in the P&I categories and then reran the model with
the influenza activity terms, i.e., the ILI terms, set to zero to provide a baseline reflecting no influenza
activity (and mortality). The difference between the estimation, including the ILI terms and the baseline
is an estimate of mortality caused by influenza alone. For example, Fig. 6 shows mortality recorded within
the P&I category for age 80 between October 1997 and December 2015 (in red), as well as mortality
predicted by the surveillance-Serfling model (in blue) and a baseline with influenza activity terms set to
zero (black dotted line); the distance between the blue line and the black dotted line provides an
estimate of mortality from influenza.
FIG 6 Surveillance-Serfling estimates of mortality per month from influenza for 80-year-old individuals.
The number of deaths is shown on the y axis, and time (month-year) from January 1996 (01-96) to
January 2016 (01-16) is shown on the x axis. The distance between the predicted number of deaths when
there is influenza activity (blue line) and the number of deaths when there is no influenza activity (dotted
black line) provides an estimate of deaths strictly due to influenza. The red line presents the raw death
counts from P&I per month. Note that between 1997 and 2004, there were no data of ILI during the low
influenza season, i.e., between June and September; the lines depicting the estimates of mortality with
influenza activity (blue line) and without influenza activity (dotted black line) are thus interrupted during
those periods, which are taken into account in this study.
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Several other models were estimated with various influenza activity indicators, such as the distribu-
tions by subtype (H1N1, H3N2) as well as measures combining ILI incidence to subtype distributions (see
reference 17 for a similar modeling strategy). Based on the Bayesian information criterion (BIC) (45), these
models did not provide better fits than the model presented above. As argued elsewhere, the consid-
eration of surveillance data may considerably improve the accuracy of the estimates in comparison with
the usual Serfling model (43, 44, 46, 47), which is often plagued by negative estimates of the number of
deaths from influenza, especially at older ages (25). It is worth noting that the surveillance-Serfling model
used here produces very few such negative estimates. Those that occur are limited almost exclusively for
summers, which are not taken into account in this analysis. The surveillance-based model also has the
advantage of fitting data from all seasons, and not exclusively from the summer seasons, as does the
traditional Serfling model; it thus produces higher mortality counts, which helps improve estimates for
the single-year age data that are used in the present study. Yet, because we used 1-year age tabulations,
some of the estimates provided here were not robust, especially for the young or the very old, where the
number of deaths (numerator) and of individuals at risk (denominator) are very small. Given the purpose
of our enquiry, i.e., to estimate mortality risk by yearly ages (and thus yearly birth cohorts), we presented
smoothed curves along the raw estimates.
Mortality rates, death rate ratios, and case fatality rate ratios. After estimating simple measures
such as raw death counts from P&I mortality and from the above Serfling models, we estimated mortality
rates due to influenza by single-year age, as well as mortality rate ratios by comparing mortality due to
influenza during the 2009 and 2013–2014 H1N1 outbreaks to the average of the 1997–1999 to
2008–2009 influenza seasons. More precisely, for each month of each outbreak (seasonal or pandemic),
we divided the number of deaths by the number of people of the same age and then took the monthly
average over the whole duration of the outbreak (e.g., from October 2009 to January 2010 during the
swine flu pandemic in the United States). Rate ratios by age were calculated by dividing the rate for
each age by the monthly averaged death rates from the influenza seasons from 1997 to 2008. These
age-specific rates were then displayed as cohorts to ease interpretation (Fig. 4). As mortality from
influenza depends not only on susceptibility to severe outcomes following infection but also on the
probability of being infected in the first place, we also used estimated attack rates from the literature.
Dividing mortality rates by these attack rates, we estimated case fatality rates, as well as case fatality rate
ratios (CFRRs), again by comparing the two H1N1 outbreaks of interest in this study to the average of the
previous 11 years of seasonal epidemics. Attack rates by age groups were available for the 2009 pandemic
in at least two meta-analyses (48, 49) and showed remarkable consistency between both studies and the
countries examined. These estimates were obtained from serological assays; many of these assays subtracted
the percentage of individuals with a titer above 40 before the outbreak from the corresponding percentage
FIG 7 Estimated attack rates by age from influenza during the 2009 H1N1 pandemic and during seasonal
outbreaks. The estimates reported by age groups by Cox et al. (30), Van Kerkhove et al. (49), Molinari et al. (53),
and Reed et al. (55) were transformed into annualized values, using linear interpolation. Estimates for the
2003–2004 season were derived from Fig. 1 in reference 54 (Johnson et al.) by subtracting sera with titers
above 40 in 2003 season from 2004 season and were also annualized using interpolation. Estimates for the
elderly (65) should be interpreted with caution in this figure (and in Fig. 5), as these attack rates pertain to
very large age groups. Instead of interpolating for this age range, we used the nominal reported values after
age 70 (i.e., 0.1) in the 2009 outbreak and after age 75 (0.09) in the seasonal outbreaks. No estimates of
age-specific attack rates were readily available for the 2013–2014 H1N1 outbreak.
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calculated after the outbreak to obtain “cumulative incidence” measures. For convenience, in Fig. 5 we used
the estimates for six age groups (i.e., 0 to 4, 5 to 17, 18 to 24, 25 to 49, 50 to 64, and 65 years) reported by
Cox et al. (30), which we transformed into annualized values using linear interpolation in Fig. 7. Figure 7 also
presents estimates from other studies, using broader age ranges.
Unfortunately, no such age-specific figures were readily available for the 2013–2014 outbreak and for
the previous 11-year period that serves as a basis for comparison for this study. Most available estimates
of attack rates by age date from the 20th century, and many go as far back as the 1960s. However, studies
based on mathematical models and empirical results of the frequency of daily contacts by age (50)
predict relatively robust distributions of the percentage of infected individuals by broadly defined age
groups, which are associated with R0, the basic reproduction number (51, 52). These studies show that,
excluding year-to-year fluctuations, on average, attack rates during seasonal outbreaks of influenza are
highest for young children and adolescents, reaching values of around 20 to 30%, and fall relatively flat
in adulthood with values between 5 and 10% for most of life. In Fig. 5, we used the empirical values
reported by Molinari et al. (53), which follow this pattern (Fig. 7). Note, however, that emergence of a
novel antigenic variant during a seasonal outbreak can also lead to disproportionate fractions of infected
children among young children, such as occurred during the 2003–2004 H3N2 seasonal outbreak in the
United Kingdom (54). This pattern at younger ages is expected, since the levels of preexisting immunity
within the population are presumed to be low in the face of significant antigenic drift, as is the case
during a pandemic (antigenic “shift”), although levels remain high at older ages. Since there were also
some variations for the age-specific attack rates in 2009 reported in numerous studies, we provide
sensitivity tests with variations in these attack rates, both for seasonal and pandemic outbreaks in the
supplemental material (see Fig. S5 in the supplemental material).
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